Medexus Pharmaceuticals Inc.
MDP
Rank in Stocks
#19024
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and... Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; GRAFAPEX, an injection to treat allogeneic hematopoietic stem cell transplantation in adult and pediatric patients, acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS); and Gleolan, an optical imaging agent for patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The companyโs products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, a ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Trecondyv, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. was founded in 2000 and is based in Toronto, Canada.
Share Price
$3.70
Last synced: 2026-11-09
Market Cap
$116.39M
Change (1 day)
2.15%
Change (1 year)
92.17%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Medexus Pharmaceuticals Inc. (MDP)
Category
Healthcare
EPS for Medexus Pharmaceuticals Inc. (MDP)
EPS as of June 2026 TTM: $-0.08
According to Medexus Pharmaceuticals Inc.'s latest financial reports, its current EPS (TTM) is $-0.08. At the end of 2025 the company had an EPS of $0.09, an increase over its 2024 EPS of $-0.01.
EPS history for Medexus Pharmaceuticals Inc. from 2012 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.08 | -184.78% |
| 2025 | $0.09 | -1,037.50% |
| 2024 | $-0.01 | -111.87% |
| 2023 | $0.08 | -142.58% |
| 2022 | $-0.19 | -89.78% |
| 2021 | $-1.86 | 693.52% |
| 2020 | $-0.23 | -34.82% |
| 2019 | $-0.36 | -1.34% |
| 2018 | $-0.36 | 73.41% |
| 2017 | $-0.21 | -26.19% |
| 2016 | $-0.28 | -56.52% |
| 2015 | $-0.66 | 942.99% |
| 2014 | $-0.06 | -76.34% |
| 2013 | $-0.27 | 33,075.00% |
| 2012 | 0.00 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $1.69 | -2,314.94% |
US
|
|
| $1.93 | -2,630.54% |
SE
|
|
| $6.91 | -9,161.60% |
FR
|
|
| $0.02 | -125.56% |
HK
|
|
| $2.71 | -3,651.51% |
IT
|
Questions about Medexus Pharmaceuticals Inc.'s earnings per share (EPS)
What is Medexus Pharmaceuticals Inc.'s earnings per share (EPS)?
Medexus Pharmaceuticals Inc.'s earnings per share (EPS) over the last twelve months is $-0.08, as of Jun 2026.
What was Medexus Pharmaceuticals Inc.'s earnings per share (EPS) in 2025?
In 2025, Medexus Pharmaceuticals Inc.'s earnings per share (EPS) was $0.09, compared with $-0.01 in 2024.
How has Medexus Pharmaceuticals Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Medexus Pharmaceuticals Inc.'s earnings per share (EPS) was highest in 2025 ($0.09) and lowest in 2021 ($-1.86).
How does Medexus Pharmaceuticals Inc.'s earnings per share (EPS) compare with similar companies?
Medexus Pharmaceuticals Inc.'s earnings per share (EPS) ($-0.08) is lower than that of all 5 similar companies listed above. The highest among them is Ipsen S.A., with $6.91.